113 completed. 113 Phase 1, 30 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 113 | Completed 113 |
| Phase 2 | 30 | Completed 30 |
Follow Carcinogenesis: new trials by email Literature Review of Carcinogenesis trials Research Report on Carcinogenesis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Engineered Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies Cyclophosphamide, Filgrastim, Fludarabine Phosphate - Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia | Phase 1 | Completed | M.D. Anderson Cancer Center | 11 | 2017-01-18 | 2023-02-16 |
| PH 1 Study to Evaluate Safety and Tolerability of XmAb14045 in Patients With CD123-expressing Hematologic Malignancies XmAb14045 - Acute Myelogenous Leukemia, B-cell Acute Lymphoblastic Leukemia | Phase 1 | Completed | Xencor, Inc. | 120 | 2016-08-01 | 2022-03-08 |
| Phase I/II Study of Bosutinib in Combination With Inotuzumab Ozogamicin in CD22-positive PC Positive ALL and CML Bosutinib, Inotuzumab Ozogamicin - B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Phase 1 / Phase 2 | Completed | M.D. Anderson Cancer Center | 22 | 2015-04-16 | 2023-07-17 |
| Natural Killer Cells Before and After Donor Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia Allogeneic Hematopoietic Stem Cell Transplantation, Bone Marrow Transplantation, Cyclophosphamide - Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Phase 1 / Phase 2 | Completed | M.D. Anderson Cancer Center | 54 | 2014-04-22 | 2024-01-24 |
| Phase I/II Study of Nilotinib/Ruxolitinb Therapy for TKI Resistant Ph-Leukemia Nilotinib, Ruxolitinib - Chronic Phase Chronic Myeloid Leukemia, Accelerated Phase Chronic Myeloid Leukemia | Phase 1 / Phase 2 | Completed | University Health Network, Toronto | 4 | 2013-08-01 | 2020-11-02 |
| Donor Natural Killer Cells and Donor Stem Cell Transplant in Treating Patients With High Risk Myeloid Malignancies Aldesleukin, Allogeneic CD56-positive CD3-negative Natural Killer Cells, Allogeneic Hematopoietic Stem Cell Transplantation - Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Erythroid Leukemia | Phase 1 / Phase 2 | Completed | M.D. Anderson Cancer Center | 63 | 2013-06-11 | 2023-11-07 |
| MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Leukemia Akt inhibitor MK2206, diagnostic laboratory biomarker analysis, pharmacological study - Accelerated Phase Chronic Myelogenous Leukemia, Acute Leukemias of Ambiguous Lineage | Phase 1 | Completed | National Cancer Institute (NCI) | 45 | 2011-01-01 | 2014-04-29 |
| Safety Study of Adjuvant Vaccine to Treat Melanoma Patients NY-ESO-1 protein; Poly-ICLC; Montanide - Melanoma | Phase 1 / Phase 2 | Completed | Nina Bhardwaj | 34 | 2010-09-01 | 2018-02-13 |
| Phase 1 Study of TG02 Citrate in Patients With Advanced Hematological Malignancies TG02 citrate, Carfilzomib, Dexamethasone - AML, ALL | Phase 1 | Completed | Tragara Pharmaceuticals, Inc. | 120 | 2010-08-01 | 2016-05-06 |
| 4'-Thio-araC (Thiarabine) in Advanced Hematologic Malignancies 3 Day Thiarabine, 5 Day Thiarabine - Leukemia | Phase 1 | Completed | M.D. Anderson Cancer Center | 31 | 2010-08-01 | 2014-06-17 |
| Study Evaluating the Tolerance and Biologic Activity of Oral Ciclopirox Olamine in Patients With Relapsed or Refractory Hematologic Malignancy Ciclopirox Olamine - Hematologic Malignancy, Acute Lymphocytic Leukemia | Phase 1 | Completed | University Health Network, Toronto | 20 | 2009-10-01 | 2015-06-22 |
| A Phase 1 Study of the HSP90 Inhibitor, STA-9090 in Subjects With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Blast-phase Chronic Myelogenous Leukemia STA-9090 (ganetespib) - Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia | Phase 1 | Completed | Synta Pharmaceuticals Corp. | 29 | 2009-08-01 | 2014-09-18 |
| Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Cord Blood Transplant for Hematologic Malignancy human myeloid progenitor cells - Leukemia, Lymphoma | Phase 1 | Completed | Cellerant Therapeutics | 30 | 2009-04-01 | 2014-10-27 |
| A Phase 1 Dose Escalation Study of TAK-901 in Subjects With Advanced Hematologic Malignancies TAK-901 - Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia | Phase 1 | Completed | Millennium Pharmaceuticals, Inc. | 31 | 2009-03-01 | 2013-07-02 |
| Donor Natural Killer Cells After Donor Stem Cell Transplant in Treating Patients With Advanced Cancer donor natural killer cell infusion - Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders | Phase 1 / Phase 2 | Completed | Asan Medical Center | 47 | 2009-01-01 | 2013-02-20 |
| Dasatinib and Vorinostat in Treating Patients With Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia or Acute Lymphoblastic Leukemia dasatinib, vorinostat, cytogenetic analysis - Leukemia | Phase 1 | Completed | City of Hope Medical Center | 5 | 2008-09-01 | 2012-07-17 |
| Nilotinib and Imatinib Mesylate After Donor Stem Cell Transplant in Treating Patients With ALL or CML nilotinib, imatinib mesylate, pharmacological study - Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission | Phase 1 / Phase 2 | Completed | Fred Hutchinson Cancer Center | 40 | 2008-08-14 | 2017-08-10 |
| Rasburicase in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer or Other Disease Undergoing Donor Stem Cell Transplant busulfan, cyclophosphamide, cyclosporin-A - Chronic Myeloproliferative Disorders, Graft Versus Host Disease | Phase 1 | Completed | Massachusetts General Hospital | 46 | 2008-01-01 | 2017-05-25 |
| Vaccine Therapy in Treating Patients Who Have Undergone a Donor Stem Cell Transplant and Have Cytomegalovirus Infection That Has Not Responded to Therapy cytomegalovirus pp65-specific cytotoxic T lymphocytes, polymerase chain reaction, diagnostic laboratory biomarker analysis - Cancer | Phase 1 | Completed | University of Louisville | 20 | 2007-06-01 | 2017-05-09 |
| Donor Natural Killer Cell Infusion in Preventing Relapse or Graft Failure in Patients Who Have Undergone Donor Bone Marrow Transplant therapeutic allogeneic lymphocytes - Cancer | Phase 1 | Completed | Asan Medical Center | 18 | 2007-05-01 | 2013-03-26 |
Showing 20 of 113. Sign in to see all of them.
Blast Crisis (112) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (96) · Leukemia, Myeloid, Acute (88) · Leukemia (70) · Leukemia, Myeloid, Accelerated Phase (65) · Myelodysplastic Syndromes (47) · Leukemia, Lymphocytic, Chronic, B-Cell (46) · Leukemia, Myeloid, Chronic-Phase (46) · Leukemia, Myelomonocytic, Chronic (45) · Burkitt Lymphoma (38) · Lymphoma, Large B-Cell, Diffuse (38) · Multiple Myeloma (38) · Congenital Abnormalities (37) · Lymphoma, Mantle-Cell (37) · Myeloproliferative Disorders (37)
Neoplasms by Histologic Type (113) · Neoplastic Processes (113) · Pathologic Processes (113) · Pathological Conditions, Signs and Symptoms (113) · Bone Marrow Diseases (112) · Cell Transformation, Neoplastic (112) · Chronic Disease (112) · Disease Attributes (112) · Hematologic Diseases (112) · Hemic and Lymphatic Diseases (112) · Leukemia, Myeloid (111) · Neoplasms (108) · Immune System Diseases (99) · Immunoproliferative Disorders (99)
Peripheral Blood Stem Cell Transplantation (16) · Filgrastim (14) · Cytarabine (12) · fludarabine phosphate (12) · Cyclophosphamide (11) · Tacrolimus (11) · Imatinib Mesylate (10) · Etoposide (9) · Busulfan (8) · Antilymphocyte Serum (5) · Cyclosporine (5) · Methotrexate (5) · Mycophenolic Acid (5) · Topotecan (5) · Vorinostat (5)
National Cancer Institute (NCI) (27) · M.D. Anderson Cancer Center (10) · Memorial Sloan Kettering Cancer Center (8) · Fred Hutchinson Cancer Center (7) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (4) · Case Comprehensive Cancer Center (3) · Vion Pharmaceuticals (3) · Virginia Commonwealth University (3) · Asan Medical Center (2) · Indiana University (2) · Jonsson Comprehensive Cancer Center (2) · National Institutes of Health Clinical Center (CC) (2) · Northwestern University (2) · Roswell Park Cancer Institute (2) · UNC Lineberger Comprehensive Cancer Center (2)
United States (105) · Canada (8) · South Korea (2) · Australia (1) · Germany (1) · Italy (1) · New Zealand (1) · Switzerland (1)
Judith E. Karp, MD (4) · Jorge Cortes (3) · Steven Grant, MD (3) · Brenda W. Cooper, MD (2) · Francis Giles (2) · Joseph G. Jurcic, MD (2) · Kyoo H. Lee, MD (2) · Mario Sznol, MD (2) · Maryam Fouladi (2) · Olatoyosi Odenike (2) · Richard K. Burt, MD (2) · Samer Srour (2) · Sergio Giralt, MD (2) · Thomas G. Martin, MD (2) · Albert von Rohr, MD (1)
PMID 12114413, PMID 15570084, PMID 16278404, PMID 16775234, PMID 17562873, PMID 17640728, PMID 17971589, PMID 18327587, PMID 18571721, PMID 19179301, PMID 20511167, PMID 20858843, PMID 20860038, PMID 20952518, PMID 21403127, PMID 21791475, PMID 22009536, PMID 22430088, PMID 23443507, PMID 24530972, PMID 26210442, PMID 34312462, PMID 37647601
U01CA062461 (6), P30CA016672 (5), P30CA006973 (4), U01CA097452 (4), P30CA043703 (3), U01CA062502 (3), U01CA062505 (3), P30CA015704 (2), P30CA016056 (2), P30CA016059 (2), U01CA062487 (2), U01CA062491 (2), U01CA069852 (2), U01CA069912 (2), U01CA070095 (2)